Pulmova
Generic Name
Respirofen 801 mg
Manufacturer
MediCare Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| pulmova 801 mg tablet | ৳ 125.00 | ৳ 1,250.00 |
Description
Overview of the medicine
Pulmova 801 mg Tablet is a novel medication indicated for the management of chronic obstructive pulmonary disease (COPD) and severe asthma. It combines potent anti-inflammatory effects with bronchodilatory action to improve lung function and reduce exacerbations.
Uses & Indications
Dosage
Adults
One 801 mg tablet once daily, preferably in the evening.
Elderly
No dose adjustment is typically required based solely on age; however, monitor renal function.
Renal_impairment
Mild to moderate renal impairment: No dose adjustment. Severe renal impairment: Use with caution, consider dose reduction.
How to Take
Pulmova 801 mg Tablet should be taken orally with water, with or without food. Do not crush, chew, or split the tablet.
Mechanism of Action
Respirofen, the active ingredient in Pulmova 801 mg, acts through a dual mechanism. It inhibits inflammatory pathways, reducing the production of pro-inflammatory mediators in the airways. Concurrently, it stimulates specific receptors on bronchial smooth muscle, leading to relaxation and widening of the airways, thereby improving airflow.
Pharmacokinetics
Onset
Bronchodilation: 30-60 minutes. Anti-inflammatory effects: within 3-7 days.
Excretion
Mainly excreted via feces (60%) and urine (40%) as metabolites.
Half life
Approximately 12-16 hours.
Absorption
Well-absorbed orally, reaching peak plasma concentrations within 2-4 hours. Bioavailability is approximately 70-80%.
Metabolism
Primarily metabolized in the liver by cytochrome P450 enzymes (CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to Respirofen or any excipients of the tablet
- •Acute bronchospasm
- •Status asthmaticus
Drug Interactions
Strong CYP3A4 inducers (e.g., Rifampicin, Phenytoin)
May decrease plasma concentrations of Respirofen, reducing its efficacy. Avoid co-administration.
Strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir)
May increase plasma concentrations of Respirofen, leading to increased risk of side effects. Co-administration should be avoided or dose adjusted with close monitoring.
Storage
Store in a cool, dry place below 30°C, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include severe tremor, palpitations, tachycardia, and hypokalemia. Treatment is symptomatic and supportive, including discontinuation of the drug and appropriate monitoring of vital signs and electrolyte levels.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit outweighs potential risk to the fetus. It is unknown if Respirofen is excreted in human milk; use with caution in breastfeeding mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from the date of manufacture.
Availability
Available in pharmacies nationwide
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Under patent
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
